Loading...

PNRF

PRFX

PAINREFORM LTD

(PRFX)

2024 6-K

Show Summary

Summary

NVIDIA Program Inclusion

19 Aug '25

Strategic Investment

13 Aug '25

Strategic Investment Agreement

10 Jul '25

AI Pilot Launch

7 May '25

Compliance Update

17 Apr '25

Nasdaq Compliance Update

11 Apr '25

Shareholder Meeting Approval

10 Apr '25

Business Update

7 Apr '25

Meeting Adjourned

3 Apr '25

Strategic Acquisition

5 Mar '25

Shareholders Meeting

27 Feb '25

Share Offering Update

26 Feb '25

DeepSolar Acquisition

18 Feb '25

Warrant Exercise Report

2 Jan '25

Trial Update

27 Dec '24

Management Change

4 Dec '24

Clinical Trial Update

20 Nov '24

Share Consolidation

18 Nov '24

Shareholder Approval

12 Nov '24

Nasdaq Communication

7 Nov '24

Meeting Adjourned

4 Nov '24

Share Offering Agreement

16 Oct '24

Extraordinary Meeting Notice

10 Oct '24

Shareholder Approval

7 Oct '24

AGM Adjourned

30 Sep '24

Warrant Exercise Report

11 Sep '24

Warrants Exercise

10 Sep '24

Share Consolidation Plan

4 Sep '24

Shareholder Meeting Notice

28 Aug '24

Annual Meeting Notice

26 Aug '24

Financial Results Announced

15 Aug '24

Shareholders Meeting Results

13 Aug '24

Extraordinary Meeting

9 Jul '24

Enrollment Completed

26 Jun '24

Nasdaq Letter Received

31 May '24

Financial Results Update

15 May '24

Securities Offering

17 Apr '24

Public Offering Pricing

16 Apr '24

Product Performance Update

9 Apr '24

Shareholder Approval

8 Apr '24

Clinical Trial Update

2 Apr '24

Extraordinary Meeting Notice

7 Mar '24

Business Update

1 Mar '24

PainReform Update

3 Jan '24

External Links:

SEC

PainReform Ltd. announced on June 26, 2024, that it successfully completed the enrollment of 428 patients in its Phase 3 trial for PRF-110, a new pain medication. Additionally, CEO Ilan Hadar will step down on September 24, 2024, with Dr. Ehud Geller appointed as interim CEO.

AI Assistant

PAINREFORM LTD

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.